Biopharma & Life Sciences
Seres Therapeutics Executive Compensation (FY25)
MCRB · Executive and director compensation, fiscal 2024 to 2025
Data as of September 7, 2026Latest filing (8-K): July 8, 2026
177 figures on this page: 172 cited to the filing that reported them, 5 calculated from figures it prints. See the citations
This company is not required to report a chief executive pay ratio.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Eric Shaff: $2,682,007 → $1,775,549 (33.8% lower)
Say-on-pay support: 64.0% → 84.5% (20.5 points higher)
Frequently asked questions
Answers drawn from the data on this page.
What was Seres Therapeutics' say-on-pay result?
Shareholders supported the say-on-pay proposal with 84.5% of votes cast for or against in favor at the meeting held July 8, 2026 for fiscal 2025.
Which companies are in Seres Therapeutics' peer group?
Companies named in the disclosed peer group include Acrivon Therapeutics, Assembly Biosciences, Atea Pharmaceuticals, Aura Biosciences and Black Diamond Therapeutics, among others.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Eric Shaff Former President and Chief Executive Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Thomas DesRosier Executive Vice President & Chief Legal Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Eric Shaff Former President and Chief Executive Officer Departed during or after this year | ◇ | — | — | ◇ | — | — | ◇ | ◇ |
Thomas DesRosier Former Co-President and Co-Chief Executive Officer and current Executive Vice President and Chief Legal Officer Departed during or after this year | ◇ | ◇ | — | ◇ | — | — | ◇ | ◇ |
Marella Thorell Former Co-President and Co-Chief Executive Officer and current Executive Vice President and Chief Financial Officer Departed during or after this year | ◇ | ◇ | ◇ | — | — | — | ◇ | ◇ |
Teresa Young Former Executive Vice President and Chief Commercial and Strategy Officer Departed during or after this year | ◇ | — | ◇ | ◇ | — | — | ◇ | ◇ |
Matthew Henn President and Chief Scientific Officer | ◇ | — | ◇ | ◇ | — | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Eric D. Shaff | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Marella Thorell | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Matthew Henn | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Matthew Henn | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Teresa L. Young | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Teresa L. Young | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Thomas J. DesRosier | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Teresa Young | Option | ◇ | — | ◇ | — |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — | |
| Eric Shaff | Option | ◇ | — | ◇ | — |
| Option | ◇ | — | ◇ | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| RSU | ◇ | ◇ | — | — | |
| Thomas DesRosier | Option | ◇ | — | ◇ | — |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Marella Thorell | Option | ◇ | — | ◇ | — |
| Option | ◇ | — | ◇ | — | |
| Matthew Henn | Option | ◇ | — | ◇ | — |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| RSU | ◇ | ◇ | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Stephen A. Berenson | ◇ | — | ◇ | — | — | — | ◇ |
Claire M. Fraser, Ph.D | ◇ | — | ◇ | — | — | — | ◇ |
Robert Rosiello | ◇ | — | ◇ | — | — | — | ◇ |
Hans-Juergen Woerle, M.D., Ph.D | ◇ | — | ◇ | — | — | — | ◇ |
Dennis A. Ausiello, M.D | ◇ | — | ◇ | — | — | — | ◇ |
Richard N. Kender Board chair | ◇ | — | ◇ | — | — | — | ◇ |
Willard H. Dere, M.D | ◇ | — | ◇ | — | — | — | ◇ |
Kurt C. Graves | ◇ | — | ◇ | — | — | — | ◇ |
Paul R. Biondi | ◇ | — | ◇ | — | — | — | ◇ |
Eric D. Shaff served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Lead independent director premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Equity is delivered as Options.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- Acrivon Therapeutics ACRV
- Assembly Biosciences ASMB
- Atea Pharmaceuticals AVIR
- Aura Biosciences AURA
- Black Diamond Therapeutics BDTX
- Enanta Pharmaceuticals ENTA
- Larimar Therapeutics LRMR
- Mersana Therapeutics MRSN
- Regulus Therapeutics RGLS
- Voyager Therapeutics VYGR
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | July 8, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | April 10, 2025 | = | ◇ | ◇ | ◇ |
| 2022 | June 22, 2023 | = | ◇ | ◇ | ◇ |
| 2021 | June 22, 2022 | = | ◇ | ◇ | ◇ |
| 2020 | June 16, 2021 | = | ◇ | ◇ | ◇ |
What this page does not include
Everything above is a fact Seres Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Seres Therapeutics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
177 figures on this page: 172 cited to the filing that reported them, 5 calculated from figures it prints.
172 cited to the filing
5 calculated from the filing
Documents cited
- 0001193125-26-298525Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001193125-26-1820362025 DIRECTOR COMPENSATION TABLE · 2025 Summary Compensation Table · ATTENDANCE BY MEMBERS OF THE BOARD OF DIRECTORS AT MEETINGS · Director Compensation · and 2 more sections
- 0001193125-25-080185Item 5.07 Submission of Matters to a Vote of Security Holders
- 0000950170-25-038441Summary Compensation Table
- 0001193125-23-173803Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001193125-22-181465Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001193125-21-195033Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Seres Therapeutics executive compensation, FY2024–FY2025.” https://intel.velarion.ai/comp/MCRB (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Seres Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Biopharma & Life Sciences rankings
Peers Seres Therapeutics discloses
The companies named in MCRB's own disclosed peer group.
Terms on this page
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}